罗格列酮对冠心病合并2型糖尿病患者IL-6、TNFα的影响

Influence of rosiglitazone maleate on interleukin-6,tumor necrosis factor α in patients with coronary heart disease and type 2 diabetes mellitus

目的:观察应用马来酸罗格列酮对冠心病合并2型糖尿病患者体内部分炎症因子水平的影响。方法:30例合并有2型糖尿病的冠心病患者在原有治疗的基础上加用马来酸罗格列酮治疗,治疗前及治疗3个月后分别检测空腹血糖、血胰岛素、糖化血红蛋白,白介素-6,肿瘤坏死因子α,比较各指标的变化。结果:患者的白介素-6、肿瘤坏死因子α出现显著下降(P<0.01),空腹血糖、血胰岛素、糖化血红蛋白亦显著下降(P<0.01;P<0.05),胰岛素敏感性指数则明显上升(P<0.05)。结论:在合并2型糖尿病的冠心病患者中应用马来酸罗格列酮治疗,不仅可以改善其糖代谢,还可降低患者体内部分炎症因子的水平,可能对冠心病患者的预后有益。

Objective To observe the influence of rosiglitazone maleate on IL-6 and TNFα in patients with coronary heart disease and type 2 diabetes mellitus. Methods Thirty patients with coronary heart disease and type 2 diabetes mellitus were treated with rosiglitazone maleate in addition to the routine therapy. Fast plasma glucose, fast insulin, HbAlc, IL-6 and TNFα were measured before and after the treatment. Results After 3 months treatment of rosiglitazone maleate, the levels of IL-6 and TNFa were decreased obviously（P〈0. 01）and the levels of fast plasma g insulin and HbAlc were also decreased significantly（P〈0.01,P〈0.05 ）,while the insu UC in ose, fast sensitive index was increased （P〈0.05）. Conclusion The use of rosiglitazone maleate not only can improve their glucose metabolism but also decrease the levels of some inflammatory markers. It may have some good effects on prognosis of the patients with coronary heart disease and type 2 diabetes mellitus.